| scholarly article | Q13442814 |
| P50 | author | Toni Gabaldón | Q27942012 |
| Joshua D Nosanchuk | Q89715713 | ||
| P2093 | author name string | Csaba Vágvölgyi | |
| Csaba Papp | |||
| Attila Gácser | |||
| László Bodai | |||
| Ewa Ksiezopolska | |||
| Hector Mora Montes | |||
| Jesse R Willis | |||
| Katica Kocsis | |||
| Nancy E Lozoya-Pérez | |||
| Renáta Tóth | |||
| P2860 | cites work | Stage specific assessment of Candida albicans phagocytosis by macrophages identifies cell wall composition and morphogenesis as key determinants | Q27346893 |
| Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes | Q27860838 | ||
| Members of the Candida parapsilosis Complex and Candida albicans are Differentially Recognized by Human Peripheral Blood Mononuclear Cells. | Q40823723 | ||
| Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints | Q41787736 | ||
| Increasing candidemia incidence from 2004 to 2015 with a shift in epidemiology in patients pre-exposed to antifungals | Q41986535 | ||
| Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis | Q42223395 | ||
| Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint | Q42545839 | ||
| Recognition and blocking of innate immunity cells by Candida albicans chitin | Q42727068 | ||
| Caspofungin-non-susceptible Candida isolates in cancer patients | Q43218252 | ||
| Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). | Q46072663 | ||
| Comparative study for 147 Candida spp. identification and echinocandins susceptibility in isolates obtained from blood cultures in 15 hospitals, Medellin, Colombia. | Q46252502 | ||
| Phenotype switching affects biofilm formation by Candida parapsilosis | Q46427787 | ||
| Candida glabrata fungemia: experience in a tertiary care center | Q46687280 | ||
| Emergence of non-Candida albicans species: Epidemiology, phylogeny and fluconazole susceptibility profile | Q49796847 | ||
| Investigating the caffeine effects in the yeast Saccharomyces cerevisiae brings new insights into the connection between TOR, PKC and Ras/cAMP signalling pathways. | Q50724092 | ||
| Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. | Q54033174 | ||
| Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes. | Q54249499 | ||
| Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia. | Q55378971 | ||
| Using the Candida Genome Database. | Q55397902 | ||
| Risk factors for Candida species colonization of neonatal intensive care unit patients | Q77341816 | ||
| Exploring the In Vitro Resistance of Candida parapsilosis to Echinocandins | Q87701710 | ||
| Differential adaptation of Candida albicans in vivo modulates immune recognition by dectin-1 | Q28486281 | ||
| Trimmomatic: a flexible trimmer for Illumina sequence data | Q29547278 | ||
| Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database | Q33826372 | ||
| Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America | Q34505582 | ||
| Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients | Q34529026 | ||
| Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. | Q34680777 | ||
| Characterization of virulence properties in the C. parapsilosis sensu lato species. | Q34850649 | ||
| Candida parapsilosis, an emerging fungal pathogen | Q34852747 | ||
| Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | Q34936576 | ||
| Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. | Q35129428 | ||
| New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species | Q35139501 | ||
| Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo | Q35666505 | ||
| Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations | Q35941237 | ||
| Topological and mutational analysis of Saccharomyces cerevisiae Fks1 | Q36156130 | ||
| Endoplasmic reticulum alpha-glycosidases of Candida albicans are required for N glycosylation, cell wall integrity, and normal host-fungus interaction | Q36313772 | ||
| Current treatment strategies for disseminated candidiasis | Q36342385 | ||
| Role of Protein Glycosylation in Candida parapsilosis Cell Wall Integrity and Host Interaction | Q36661065 | ||
| Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. | Q36845482 | ||
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. | Q38058556 | ||
| Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines | Q38222481 | ||
| Mechanisms of Antifungal Drug Resistance | Q38266675 | ||
| The TOPCONS web server for consensus prediction of membrane protein topology and signal peptides | Q38390019 | ||
| Mechanisms of echinocandin antifungal drug resistance | Q38550402 | ||
| A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility | Q39686624 | ||
| Antifungal susceptibility testing of Candida isolates from the Candida surveillance study | Q39901515 | ||
| Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: A 10-year study | Q40101767 | ||
| Soluble Dectin-1 as a tool to detect beta-glucans | Q40255298 | ||
| Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility | Q40677960 | ||
| Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains | Q40750655 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | abiotic stress | Q4667893 |
| Candida parapsilosis | Q144068 | ||
| microevolution | Q680054 | ||
| P577 | publication date | 2018-11-14 | |
| P1433 | published in | mSphere | Q27727104 |
| P1476 | title | Echinocandin-Induced Microevolution of Candida parapsilosis Influences Virulence and Abiotic Stress Tolerance | |
| P478 | volume | 3 |
| Q96306121 | Prevalence and Clonal Distribution of Azole-Resistant Candida parapsilosis Isolates Causing Bloodstream Infections in a Large Italian Hospital | cites work | P2860 |
Search more.